Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update

Assembly Biosciences, Inc. (NASDAQ:ASMB) was the recipient of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 15,900 shares, a growth of 37.1% from the November 15th total of 11,600 shares. Based on an average trading volume of 33,200 shares, the short-interest ratio is currently 0.5 days. Approximately 0.4% of the shares of the stock are sold short.

Analyst Ratings Changes

Several research analysts have weighed in on ASMB shares. HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a research note on Tuesday, September 24th. Jefferies Financial Group upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $2.00 to $35.00 in a research note on Friday, September 20th.

Insider Buying and Selling

In other news, major shareholder Alexander Schornstein purchased 10,000 shares of the company’s stock in a transaction dated Tuesday, October 8th. The stock was acquired at an average price of $14.58 per share, for a total transaction of $145,800.00. Following the completion of the transaction, the insider now directly owns 703,113 shares in the company, valued at $10,251,387.54. This represents a 1.44 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 394 shares of company stock valued at $5,894 over the last quarter. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Assembly Biosciences

A number of institutional investors have recently made changes to their positions in the business. FMR LLC lifted its position in shares of Assembly Biosciences by 29.7% in the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 3,635 shares during the last quarter. Acadian Asset Management LLC raised its stake in Assembly Biosciences by 131.0% during the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 7,690 shares during the period. Renaissance Technologies LLC lifted its holdings in Assembly Biosciences by 39.2% in the second quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after acquiring an additional 15,451 shares during the last quarter. Finally, Armistice Capital LLC acquired a new stake in shares of Assembly Biosciences during the 2nd quarter worth approximately $6,421,000. 19.92% of the stock is owned by institutional investors and hedge funds.

Assembly Biosciences Stock Up 0.2 %

Shares of Assembly Biosciences stock traded up $0.03 during trading hours on Friday, hitting $15.38. 10,278 shares of the company’s stock traded hands, compared to its average volume of 33,699. Assembly Biosciences has a twelve month low of $8.82 and a twelve month high of $19.93. The stock has a 50 day simple moving average of $16.42 and a 200-day simple moving average of $15.59.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.